Certolizumab pegol 200 mg sc (with or without MTX) vs placebo (with or without MTX)
ACR 50% improvement · patients with rheumatoid arthritis in adults
Certolizumab pegol 200 mg sc (with or without MTX) leads to higher ACR 50% improvement compared with placebo (with or without MTX) (high certainty).
1 finding from 1 review
- Certolizumab pegol (CDP870) for rheumatoid arthritis in adults 2017 · Cochrane Headline outcomes onlyRR 3.8 [2.42, 5.95]5 studies · 1445 participantsHigh